HK1199842A1 - 抗涎免凝集素- 抗體及其用途 - Google Patents

抗涎免凝集素- 抗體及其用途

Info

Publication number
HK1199842A1
HK1199842A1 HK15100426.7A HK15100426A HK1199842A1 HK 1199842 A1 HK1199842 A1 HK 1199842A1 HK 15100426 A HK15100426 A HK 15100426A HK 1199842 A1 HK1199842 A1 HK 1199842A1
Authority
HK
Hong Kong
Prior art keywords
siglec
antibodies
Prior art date
Application number
HK15100426.7A
Other languages
English (en)
Inventor
John ELVIN
Catherine Huntington
John Trowsdale
Alexander Barrow
Huan Cao
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of HK1199842A1 publication Critical patent/HK1199842A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
HK15100426.7A 2011-09-09 2015-01-15 抗涎免凝集素- 抗體及其用途 HK1199842A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161532658P 2011-09-09 2011-09-09
PCT/EP2012/067454 WO2013034660A1 (en) 2011-09-09 2012-09-06 Anti-siglec-15 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
HK1199842A1 true HK1199842A1 (zh) 2015-07-24

Family

ID=46829748

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15100426.7A HK1199842A1 (zh) 2011-09-09 2015-01-15 抗涎免凝集素- 抗體及其用途

Country Status (8)

Country Link
US (2) US9447192B2 (zh)
EP (1) EP2753356B1 (zh)
JP (2) JP6216317B2 (zh)
AU (1) AU2012306341B2 (zh)
CA (1) CA2848074A1 (zh)
ES (1) ES2908046T3 (zh)
HK (1) HK1199842A1 (zh)
WO (1) WO2013034660A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447192B2 (en) * 2011-09-09 2016-09-20 Medimmune Limited Anti-Siglec-15 antibodies and uses thereof
RU2761980C2 (ru) * 2015-11-10 2021-12-14 Йейл Юниверсити Композиции и способы лечения аутоиммунных заболеваний и рака
US10365913B2 (en) * 2016-05-12 2019-07-30 Symantec Corporation Systems and methods for updating network devices
KR20240035625A (ko) 2016-09-21 2024-03-15 넥스트큐어 인코포레이티드 Siglec-15를 위한 항체 및 이의 사용 방법
US20220348682A1 (en) 2018-08-30 2022-11-03 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
US11104732B2 (en) * 2019-04-24 2021-08-31 Innovative Cellular Therapeutics Holdings, Ltd. Reducing immune inhibition induced by SIGLEC-15
CN111378043B (zh) * 2020-02-19 2021-02-09 南京医科大学 一种具有中和作用的人鼠嵌合抗Siglec-15全分子IgG及其制备方法和应用
EP4126938A4 (en) 2020-03-27 2024-04-10 Biosion Inc ANTIBODIES BINDING TO SIGLEC15 AND THEIR USES
CN117295766A (zh) * 2021-03-19 2023-12-26 艾佩斯瑞生物制药公司 对唾液酸结合性ig样凝集素15具特异性的抗体及其用途
WO2022237819A1 (zh) * 2021-05-13 2022-11-17 信达生物制药(苏州)有限公司 抗Siglec-15抗体及其用途
CN113801230B (zh) * 2021-09-29 2023-07-04 中国人民解放军军事科学院军事医学研究院 一种人抗Siglec-15抗体及其应用
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3060165A (en) 1962-10-23 Preparation of toxic ricin
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5079163A (en) 1985-03-29 1992-01-07 Cetus Corporation Recombinant ricin toxin fragments
WO1986005807A1 (en) 1985-04-01 1986-10-09 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4689401A (en) 1986-03-06 1987-08-25 Cetus Corporation Method of recovering microbially produced recombinant ricin toxin a chain
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ATE151110T1 (de) 1988-09-02 1997-04-15 Protein Eng Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
IE921169A1 (en) 1991-04-10 1992-10-21 Scripps Research Inst Heterodimeric receptor libraries using phagemids
EP0590067A1 (en) 1991-06-14 1994-04-06 Xoma Corporation Microbially-produced antibody fragments and their conjugates
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU696293B2 (en) 1993-12-08 1998-09-03 Genzyme Corporation Process for generating specific antibodies
ATE300610T1 (de) 1994-01-31 2005-08-15 Univ Boston Bibliotheken aus polyklonalen antikörpern
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
CA2761116A1 (en) 1995-04-27 1996-10-31 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
KR20080059467A (ko) 1996-12-03 2008-06-27 아브게닉스, 인크. 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
US7227002B1 (en) 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
GB2339430A (en) 1997-05-21 2000-01-26 Biovation Ltd Method for the production of non-immunogenic proteins
AU8619698A (en) 1997-07-25 1999-02-16 Ban C. H. Tsui Devices, systems and methods for determining proper placement of epidural catheters
JP2002534959A (ja) 1998-12-08 2002-10-22 バイオベーション リミテッド 免疫原性タンパク質の改変方法
US20020110862A1 (en) * 2000-10-06 2002-08-15 George Foussias Novel Siglec-like gene
US7319139B2 (en) 2001-01-29 2008-01-15 Biogen Idec, Inc. TAG-72 specific CH2 domain deleted antibodies
EP1629011B1 (en) * 2003-05-31 2010-01-13 Micromet AG Human anti-human cd3 binding molecules
GB0521991D0 (en) * 2005-10-28 2005-12-07 Univ Dundee Siglec-9 binding agents
US8168181B2 (en) * 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
DK2206727T3 (en) * 2007-10-11 2015-07-06 Daiichi Sankyo Co Ltd ANTIBODY SPECIFIC TO OSTEOKLASTRELATERET PROTEIN Siglec-15
AU2010235453B2 (en) 2009-04-09 2013-10-03 Daiichi Sankyo Company,Limited Anti-Siglec-15 antibody
US9447192B2 (en) * 2011-09-09 2016-09-20 Medimmune Limited Anti-Siglec-15 antibodies and uses thereof

Also Published As

Publication number Publication date
JP6216317B2 (ja) 2017-10-18
JP2014527804A (ja) 2014-10-23
WO2013034660A1 (en) 2013-03-14
CA2848074A1 (en) 2013-03-14
US20170029503A1 (en) 2017-02-02
US20150037356A1 (en) 2015-02-05
US9994636B2 (en) 2018-06-12
AU2012306341A1 (en) 2014-03-20
US9447192B2 (en) 2016-09-20
JP6326479B2 (ja) 2018-05-16
ES2908046T3 (es) 2022-04-27
JP2017101032A (ja) 2017-06-08
AU2012306341B2 (en) 2017-08-31
EP2753356A1 (en) 2014-07-16
EP2753356B1 (en) 2021-12-22
WO2013034660A9 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
HUS2100034I1 (hu) ANGPTL3-ellenes antitestek és alkalmazásaik
IL288203B (en) Meditops and Meditop binding antibodies and their use
IL281250A (en) Anti-PHF-tau antibodies and uses thereof
IL232399A0 (en) Anti-2fgfr antibodies and their use
HK1207092A1 (zh) 抗- 抗體及其用途
EP2756094A4 (en) ANTI-B7-H4 ANTIBODIES AND USES THEREOF
DK2729170T3 (en) Antibody variants and uses thereof
HRP20190358T1 (hr) Antitijela protiv asic1 i njihova primjena
HK1199842A1 (zh) 抗涎免凝集素- 抗體及其用途
GB201208372D0 (en) Antibodies and uses thereof